Technology ID
TAB-4972
Advanced Prime-Boost Vaccine Strategy Using LCMV Vectors for Lentiviral Infection Prevention
E-Numbers
E-186-2011-0
Lead Inventor
Flatz, Lukas
Lead IC
NIAID
Co-Inventors
Nabel, Gary
Cheng, Cheng
Ko, Sung-Youl
Kong, Wing-pui
ICs
NIAID
Applications
Therapeutics
Therapeutic Areas
Infectious Disease
Development Stages
Discovery
Research Products
Plasmids/Vectors
This technology presents a novel prime-boost vaccine strategy using recombinant Lymphocytic Choriomeningitis Virus (LCMV) vectors to protect against lentiviral infections, particularly HIV. The approach involves different prime-boost combinations with LCMV vectors expressing HIV proteins, demonstrating efficacy in eliciting immune responses. The strategy, developed by a team including Gary Nahel, Sung-Youl Ko, Cheng Cheng, Wing-pui Kong, and Lukas Platz, has been shown to effectively stimulate T cell and antibody responses, providing protection against viral challenges. This innovative approach holds promise for improving vaccination strategies against lentiviral infections.
Commercial Applications
The prime-boost vaccine strategy utilizing recombinant Lymphocytic Choriomeningitis Virus (LCMV) vectors has broad potential applications beyond HIV prevention. This innovative approach could be adapted to target other lentiviral infections, such as simian immunodeficiency virus (SIV) in non-human primates, as well as lentiviruses affecting other animal species. Furthermore, the flexibility of the prime-boost combinations could allow for the development of vaccines against other viral diseases, leveraging the strong immune responses elicited by this strategy. Additionally, this technology may have implications for improving vaccine efficacy against other challenging pathogens, opening up new avenues for vaccine development and infectious disease control.
Competitive Advantages
The prime-boost vaccine strategy utilizing recombinant Lymphocytic Choriomeningitis Virus (LCMV) vectors offers several competitive advantages over traditional vaccine approaches. This innovative strategy has demonstrated superior efficacy in eliciting immune responses, including robust T cell and antibody responses, which are crucial for protecting against viral infections like HIV. Additionally, the flexibility of the prime-boost combinations allows for tailored immunization regimens to optimize immune responses. The technology's ability to stimulate both cellular and humoral immunity makes it a promising candidate for combating lentiviral infections. Furthermore, the expertise and collaboration of the inventors, including Gary Nahel, Sung-Youl Ko, Cheng Cheng, Wing-pui Kong, and Lukas Platz, ensure the continued advancement and potential commercialization of this groundbreaking vaccine strategy.
Licensing Contact: